Drugs / GX-19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04445389 | Jun → Dec 2020 | COVID-19 | Genexine, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-06-11 | Genexine, Inc. | Regulatory Genexine, COVID-19 preventive vaccine, GX-19, clinical 1/2 phase approval genexine.com ↗
Genexine(CEO, Young Chul Sung) said that it is the first domestic pharmaceutical company to have been approved for clinical phase 1/2a of GX-19, which is a DNA vaccine against COVID-19, by the Ministry of Food and Drug Safety. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-11 | Genexine, Inc. | Genexine, COVID-19 preventive vaccine, GX-19, clinical 1/2 phase approval genexine.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GX-19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04445389 ↗ |
| Modality | Vaccine | “COVID-19 Preventive DNA Vaccine” NCT04445389 ↗ |
| Route | Intramuscular | “intramuscularly administration” NCT04445389 ↗ |